UH Seidman is Actively Enrolling Patients in CAR-T Clinical Trials
October 03, 2019
UH Seidman Cancer Center Update | October 2019
CASE 2417 – Point of Care Manufactured AntiCD19 CAR-T Cells for Relapsed or Refractory Non Hodgkin’s Lymphoma
• This Phase I investigator-initiated trial evaluates the use of rapid, local manufacture of AntiCD19 CAR-T cells for the treatment of relapsed/refractory lymphomas. CAR-T cells are manufactured in the UH Seidman Cancer Center Cellular Therapy Lab for 8-12 days, allowing for treatment of patients who would otherwise not be able to wait for other cellular therapies manufactured off-site.
• This trial is actively enrolling. Patients with CD19+ lymphomas who have failed two or more lines of therapy are eligible.
• ClinicalTrials.gov #NCT03434769
JUNO 1417 ¬– AntiCD19 CAR-T Cells for Treatment of Chronic Lymphocytic Leukemia
• This Phase I industry-based trial examines the safety and activity of anti CD19 CAR-T cells in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma.
• This study is actively enrolling. Eligible patients include: High risk CLL patients who have failed 2 lines of therapy or standard risk patients who have failed 3 lines of treatment.